Update on Survival in Osteosarcoma

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Orthopedic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Meyers P.A.
        • Schwartz C.L.
        • Krailo M.
        • et al.
        Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
        J Clin Oncol. 2005; 23: 2004-2011
        • Ferrari S.
        • Meazza C.
        • Palmerini E.
        • et al.
        Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
        Tumori. 2014; 100: 612-619
        • Anninga J.K.
        • Gelderblom H.
        • Fiocco M.
        • et al.
        Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?.
        Eur J Cancer. 2011; 47: 2431-2445
        • Allison D.C.
        • Carney S.C.
        • Ahlmann E.R.
        • et al.
        A meta-analysis of osteosarcoma outcomes in the modern medical era.
        Sarcoma. 2012; 2012: 704872
      1. Available at: http://nccd.cdc.gov/USCS/childhoodcancerdetailedbyICCC.aspx. Accessed June 17, 2015.

        • Rosenberg A.E.
        • Cleton-Jansen A.-M.
        • de Pinieux G.
        • et al.
        Conventional osteosarcoma.
        in: Fletcher C.D.M. Bridge J.A. Hogendoorn P.C.W. WHO classification of tumours of soft tissue and bone. 4th edition. IARC, Lyon (France)2013: 282
        • Heath F.A.
        Osteo-sarcoma of the femur and lung.
        Br Med J. 1877; 2: 921
        • Duchman K.R.
        • Gao Y.
        • Miller B.J.
        Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database.
        Cancer Epidemiol. 2015; 39: 593-599
        • Bruland O.S.
        • Høifødt H.
        • Saeter G.
        • et al.
        Hematogenous micrometastases in osteosarcoma patients.
        Clin Cancer Res. 2005; 11: 4666-4673
        • Kager L.
        • Zoubek A.
        • Potschger U.
        • et al.
        Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
        J Clin Oncol. 2003; 21: 2011-2018
        • Rosen G.
        • Marcove R.C.
        • Huvos A.G.
        Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy.
        J Cancer Res Clin Oncol. 1983; 106: 55-67
        • Eilber F.
        • Giuliano A.
        • Eckardt J.
        • et al.
        Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.
        J Clin Oncol. 1987; 5: 21-26
        • Bernthal N.M.
        • Federman N.
        • Eilber F.R.
        • et al.
        Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma.
        Cancer. 2012; 118: 5888-5893
        • Link M.P.
        • Goorin A.M.
        • Horowitz M.
        • et al.
        Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study.
        Clin Orthop Relat Res. 1991; 270: 8-14
        • Link M.P.
        • Goorin A.M.
        • Miser A.W.
        • et al.
        The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.
        N Engl J Med. 1986; 314: 1600-1606
        • Rosen G.
        Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience.
        Orthopedics. 1985; 8: 659-664
        • Slade A.D.
        • Warneke C.L.
        • Hughes D.P.
        • et al.
        Effect of concurrent metastatic disease on survival in children and adolescents undergoing lung resection for metastatic osteosarcoma.
        J Pediatr Surg. 2015; 50: 157-160
        • Briccoli A.
        • Rocca M.
        • Salone M.
        • et al.
        High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005.
        Surg Oncol. 2010; 19: 193-199
        • Salah S.
        • Toubasi S.
        Factors predicting survival following complete surgical remission of pulmonary metastases in osteosarcoma.
        Mol Clin Oncol. 2015; 3: 157-162
        • Gelderblom H.
        • Jinks R.C.
        • Sydes M.
        • et al.
        Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.
        Eur J Cancer. 2011; 47: 895-902
        • Bielack S.
        • Jurgens H.
        • Jundt G.
        • et al.
        Osteosarcoma: the COSS experience.
        Cancer Treat Res. 2009; 152: 289-308
        • Berner K.
        • Hall K.S.
        • Monge O.R.
        • et al.
        Prognostic factors and treatment results of high-grade osteosarcoma in Norway: a scope beyond the “classical” patient.
        Sarcoma. 2015; 2015: 516843
        • Bacci G.
        • Bertoni F.
        • Longhi A.
        • et al.
        Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor.
        Cancer. 2003; 97: 3068-3075
        • Hauben E.I.
        • Weeden S.
        • Pringle J.
        • et al.
        Does the histologic subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.
        Eur J Cancer. 2002; 38: 1218-1225
        • Song W.S.
        • Kong C.B.
        • Jeon D.G.
        • et al.
        Prognosis of extremity osteosarcoma in patients aged 40-60 years: a cohort/case controlled study at a single institute.
        Eur J Surg Oncol. 2010; 36: 483-488
        • Longhi A.
        • Errani C.
        • Gonzales-Arabio D.
        • et al.
        Osteosarcoma in patients older than 65 years.
        J Clin Oncol. 2008; 26: 5368-5373
        • Harting M.T.
        • Lally K.P.
        • Andrassy R.J.
        • et al.
        Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients.
        J Cancer Res Clin Oncol. 2010; 136: 561-570
        • Shaylor P.J.
        • Peake D.
        • Grimer R.J.
        • et al.
        Paget’s osteosarcoma—no cure in sight.
        Sarcoma. 1999; 3: 191-192
        • Mankin H.J.
        • Hornicek F.J.
        Paget’s sarcoma: a historical and outcome review.
        Clin Orthop Relat Res. 2005; 438: 97-102
        • Luetke A.
        • Meyers P.A.
        • Lewis I.
        • et al.
        Osteosarcoma treatment–Where do we stand? A state of the art review.
        Cancer Treat Rev. 2014; 40: 523-532
        • Benjamin R.S.
        • Patel S.R.
        Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy.
        Cancer Treat Rev. 2009; 152: 355-363
        • Collins M.
        • Wilhelm M.
        • Conyers R.
        • et al.
        Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.
        J Clin Oncol. 2013; 31: 2303-2312
        • Su W.
        • Lai Z.
        • Wu F.
        • et al.
        Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials.
        Med Oncol. 2015; 32: 481
        • Xiao X.
        • Wang W.
        • Wang Z.
        The role of chemotherapy for metastatic, relapsed, and refractory osteosarcoma.
        Pediatr Drugs. 2014; 16: 503-512
        • Whelan J.S.
        • Bielack S.S.
        • Marina N.
        • et al.
        EURAMOS-1, an international randomized study for osteosarcoma: results from pre-randomisation treatment.
        Ann Oncol. 2015; 26: 407-414
        • Saumet L.
        • Deschamps F.
        • Marec-Berard P.
        • et al.
        Radiofrequency ablation of metastases from osteosarcoma in patients under 25 years: the SCFE experience.
        Pediatr Hematol Oncol. 2015; 32: 41-49
        • Hawkins D.S.
        • Arndt C.A.
        Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
        Cancer. 2003; 98: 2447-2456
        • Ferrari S.
        • Briccoli A.
        • Mercuri M.
        • et al.
        Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival.
        J Clin Oncol. 2003; 21: 710-715
        • Daw N.C.
        • Chou A.J.
        • Jaffe N.
        • et al.
        Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review.
        Br J Cancer. 2015; 112: 278-282
        • Enneking W.F.
        • Spanier S.S.
        • Goodman M.A.
        A system for the surgical staging of musculoskeletal sarcoma.
        Clin Orthop Relat Res. 1980; 153: 103-120
        • Bus M.P.
        • Bramer J.A.
        • Schaap G.R.
        • et al.
        Hemicortical resection and inlay allograft reconstruction for primary bone tumors: a retrospective evaluation in the Netherlands and review of the literature.
        J Bone Joint Surg Am. 2015; 97: 738-750
        • Hawkins D.S.
        • Conrad 3rd, E.U.
        • Butrynski J.E.
        • et al.
        [F-18]-flurordeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
        Cancer. 2009; 115: 3519-3525
        • Byun B.H.
        • Kong C.B.
        • Lim I.
        • et al.
        Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
        J Nucl Med. 2013; 54: 1053-1059
        • Li J.
        • Wang Z.
        • Guo Z.
        • et al.
        Precise resection and biological reconstruction under navigation guidance for young patients with juxta-articular bone sarcoma in lower extremity: preliminary report.
        J Pediatr Orthop. 2014; 34: 101-108
        • Jeys L.
        • Matharu G.S.
        • Nandra R.S.
        • et al.
        Can computer-assisted surgery reduce the risk of an intralesional margin and reduce the rate of local recurrence in patients with a tumour of the pelvis or sacrum?.
        Bone Joint J. 2013; 95-B: 1417-1424
        • Reddy K.I.
        • Wafa H.
        • Gaston C.L.
        • et al.
        Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins?.
        Bone Joint J. 2015; 97-B: 115-120
        • Bertrand T.E.
        • Cruz A.
        • Binitie O.
        • et al.
        Do surgical margins affect local recurrence and survival in extremity, nonmetastatic, high-grade osteosarcoma?.
        Clin Orthop Relat Res. 2015; ([Epub ahead of print])
        • Abudu A.
        • Sferopoulous N.K.
        • Tillman R.M.
        • et al.
        The surgical treatment and outcome of pathological fractures in localised osteosarcoma.
        J Bone Joint Surg Br. 1996; 78: 694-698
        • Jaffe N.
        • Spears R.
        • Eftekhari F.
        • et al.
        Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survival.
        Cancer. 1987; 59: 701-709
        • Bacci G.
        • Ferrari S.
        • Longhi A.
        • et al.
        Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy.
        Acta Orthop Scand. 2003; 74: 449-454
        • Salunke A.A.
        • Chen Y.
        • Tan J.H.
        • et al.
        Does a pathological fracture affect the prognosis in patients with osteosarcoma of the extremities?.
        Bone Joint J. 2014; 96-B: 1396-1403
        • Sun L.
        • Li Y.
        • Zhang J.
        • et al.
        Prognostic value of pathologic fracture in patients with high grade localized osteosarcoma: a systemic review and meta-analysis of cohort studies.
        J Orthop Res. 2015; 33: 131-139
        • Mattei P.
        Surgery for metastatic disease.
        Curr Opin Pediatr. 2013; 25: 362-367
        • Janeway K.A.
        • Grier H.E.
        Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
        Lancet Oncol. 2010; 11: 670-678
        • Lee J.S.
        • DuBois S.G.
        • Boscardin W.J.
        • et al.
        Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma.
        Cancer. 2014; 120: 3987-3993
        • Fidler M.M.
        • Frobisher C.
        • Guha J.
        • et al.
        Long-term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study.
        Br J Cancer. 2015; 112: 1857-1865
        • Ghert M.
        • Deheshi B.
        • Holt G.
        • et al.
        Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study.
        BMJ Open. 2012; 2 ([pii:e002197])
        • Meyers P.A.
        • Schwartz C.L.
        • Krailo M.D.
        • et al.
        Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the Children’s Oncology Group.
        J Clin Oncol. 2008; 26: 633-638
        • Rivera-Valentin R.K.
        • Zhu L.
        • Hughes D.P.M.
        Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy.
        Pediatr Drugs. 2015; 17: 257-271
        • Kansara M.
        • Teng M.W.
        • Smyth M.J.
        • et al.
        Translational biology of osteosarcoma.
        Nat Rev Cancer. 2014; 14: 722-735